39794-75-7

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl (p-tosyloxy)acetate is used as a key intermediate in the synthesis of Tosylglycolic Acid (T664020), which is an essential precursor for the production of Cefmetazole (C242850). Cefmetazole is a semi-synthetic antibiotic belonging to the cephalosporin class, widely used for treating various bacterial infections.
Ethyl (p-tosyloxy)acetate is used as a synthetic intermediate for [the development of pharmaceutical compounds] because of its unique chemical structure and reactivity, which allows for the creation of a wide range of therapeutic agents.
Used in Organic Chemistry:
In the field of organic chemistry, Ethyl (p-tosyloxy)acetate is used as a versatile building block for [the synthesis of various organic compounds] due to its ability to undergo a range of chemical reactions, such as nucleophilic substitutions, eliminations, and rearrangements. This makes it a valuable tool for the development of new molecules with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 503-68-4 diazoacetic acid 
• 104-15-4 toluene-4-sulfonic acid 
• 109-99-9 tetrahydrofuran 
• 623-73-4 diazoacetic acid ethyl ester 
• 64-17-5 ethanol 
• 623-50-7 ethyl 2-hydroxyacetate 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 6975-17-3 ethyl 1-oxaspiro[2.5]octane-2-carboxylate 
• 16124-65-5 [4-(4-Nitro-phenylamino)-phenoxy]-acetic acid ethyl ester 
• 39794-77-9 2-(4-methylphenyl)sulfonyloxyacetic acid 
• 1334484-14-8 2-((2,5-dimethoxybenzyl)(2-phenoxyphenyl)amino)-2-oxoethyl-4-methylbenzenesulfonate 
• 78066-05-4 ethyl 2-(p-fluorophenylthiaoxy)acetate 
• 14738-27-3 ethyl (p-tolylthio)acetate 
• 75032-27-8 ethyl <(p-nitrophenyl)thio>acetate 
• 82187-66-4 ethyl 2-(thiophen-2-sulfanyl)acetate 
• 959119-78-9 4-(2-(tosyloxy)acetamido)benzoic acid 
• 501919-59-1 2-hydroxy-4-[[2-[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino]benzoic acid 
• 158818-29-2 N-phenyl-O-tosylglycolamide 

Relevant academic research and scientific papers

Sulfur-containing andrographolide derivative and pharmaceutical composition and synthesis method thereof and application of sulfur-containing andrographolide derivative in preparation of medicine for treating prostatic cancers

The invention relates to an andrographolide derivative shown in the following general formula (I) or general formula (II) (please see the formula in the description) and a preparation method thereof and a composition containing the compound shown in the g

Synthesis of thioether andrographolide derivatives and their inhibitory effect against cancer cells

A series of novel thioether andrographolide derivatives were synthesized by incorporating various aromatic (or heteroaromatic) substituents into C-12 or 14-OH. A total of 38 andrographolide derivatives were prepared and evaluated for their in vitro inhibi

Nonmetal catalyzed insertion reactions of diazocarbonyls to acid derivatives in fluorinated alcohols

The insertion reaction of diazocarbonyls to acids could be performed smoothly in fluorinated alcohols in the absence of metal catalyst. This new procedure allowed the chemoselective preparation of various functionalized compounds such as acyloxyesters, depsipeptides, and sulfonate, phosphonate, or boronate derivatives.

Synthesis of [11C]PBR06 and [18F]PBR06 as agents for positron emission tomographic (PET) imaging of the translocator protein (TSPO)

The translocator protein 18 kDa (TSPO) is an attractive target for molecular imaging of neuroinflammation and tumor progression. [ 18F]PBR06, a fluorine-18 labeled form of PBR06, is a promising PET TSPO radioligand originally developed at NIMH.

SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growthinvitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. The invention further includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a method of identifying anti-cancer agents.

Synthesis of no-carrier-added [18F]fluoroacetate

To synthesize no-carrier-added potassium [18F]fluoroacetate, O-mesyl glycolate ethyl ester and O-tosyl glycolate ethyl ester were synthesized as precursors. These precursors were radiolabeled by reacting with dried tetrabutylammonium [18/

Reaction of Carbenes with Cyclic Ethers in the Presence of Nucleophiles. A Three-Component Coupling Reaction

Ternary reaction systems consisting of a carbene , a cyclic ether (THF, THP) and a protic nucleophile (alcohol, water, carboxylic acid, thiol, or amine) give the corresponding three-component coupling products which are produced via ethereal oxonium ylide intermediates.The mechanism leading to the product formation has been studied in which protonation of carbenes is excluded.